Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the US.
Field
David
D
Division of Child Health, Leicester University Medical School, Leicester LE1 5WW, United Kingdom. david.field@uhl-tr.nhs.uk
Normand
Charles
C
Elbourne
Diana
D
D003362:Cost-Benefit Analysis; D015199:Extracorporeal Membrane Oxygenation / Q000191:economics*; D006801:Humans; D000860:Hypoxia / Q000191:economics* / Q000628:therapy*; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000191:economics* / Q000627:therapeutic use*; D012131:Respiratory Insufficiency / Q000191:economics* / Q000628:therapy*; D014665:Vasodilator Agents / Q000191:economics* / Q000627:therapeutic use*
D014665:Vasodilator Agents; D009569:Nitric Oxide